Antibody response and avidity of respiratory syncytial virus‐specific total IgG, IgG1, and IgG3 in young children
- 11 August 2011
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (10) , 1826-1833
Abstract
Respiratory syncytial virus (RSV) is a major cause of acute respiratory disease in infants and young children. Considering that several aspects of the humoral immune response to RSV infection remain unclear, this study aimed to investigate the occurrence, levels, and avidity of total IgG, IgG1, and IgG3 antibodies against RSV in serum samples from children ≤5 years old. In addition, a possible association between antibody avidity and severity of illness was examined. The occurrence and levels of RSV‐specific IgG depended on age, with infants <3 months old displaying high levels of antibodies, which were probably acquired from the mother. Children ≥24 months old also showed frequent occurrence and high levels of IgG, which was produced actively during infection. In addition, the avidity assay showed that the avidity of RSV‐specific total IgG and IgG1 was lower in infants <3 months old who had acute respiratory disease than in age‐matched controls. The avidity of RSV‐specific IgG detected in children ≥24 months old with lower respiratory infection was lower than that in children with upper respiratory infection. These results indicate that the presence of high avidity RSV‐specific IgG antibodies may lead to better protection against RSV infection in children <3 months old, who may have a lower probability of developing disease of increased severity. In addition, children ≥24 months old with RSV‐specific IgG antibodies of low avidity tended to develop more severe RSV illness. These findings may be helpful in establishing vaccination schedules when a vaccine becomes available. J. Med. Virol. 83:1826–1833, 2011.Keywords
This publication has 31 references indexed in Scilit:
- Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMTPediatric Pulmonology, 2010
- Seasonal Variation of Maternally Derived Respiratory Syncytial Virus Antibodies and Association with Infant Hospitalizations for Respiratory Syncytial VirusThe Journal of Pediatrics, 2009
- Epidemiological assessment of Respiratory Syncytial Virus infection in hospitalized infants, during the season 2005–2006 in Palermo, ItalyItalian Journal of Pediatrics, 2009
- Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseNature Medicine, 2008
- Young Infants Can Develop Protective Levels of Neutralizing Antibody after Infection with Respiratory Syncytial VirusThe Journal of Infectious Diseases, 2008
- Viral and Host Factors in Human Respiratory Syncytial Virus PathogenesisJournal of Virology, 2008
- Respiratory Syncytial Virus Infection and Disease in Infants and Young Children Observed from Birth in Kilifi District, KenyaClinical Infectious Diseases, 2008
- Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory TractJournal of Molecular Biology, 2007
- Influence of Maternal Antibodies on Neonatal Immunization against Respiratory VirusesClinical Infectious Diseases, 2001
- The antibody response to primary and secondary infection with respiratory syncytial virus: Kinetics of class-specific responsesThe Journal of Pediatrics, 1980